Paratek Pharmaceuticals Inc   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1996)

Organization Overview

First Clinical Trial
2007
NCT03716024
First Marketed Drug
2018
omadacycline (nuzyra)
First NDA Approval
2018
omadacycline (nuzyra)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Paratek Pharmaceuticals | Paratek Pharmaceuticals Inc | PARATEK PHARMS INC

Active Ingredients

Marketed Drugs (1)

omadacycline (nuzyra) (2018 NDA)

Drugs in Phase 4 Trials (1)

omadacycline (nuzyra) (15 trials)

Drugs in Phase 3 Trials (5)

Key: Paratek Pharmaceuticals Inc (2) Acquired (3)

calcitriol (rocaltrol) (8 trials)

docetaxel (taxotere) (3 trials)

linezolid (zyvox) (5 trials)

moxifloxacin (avelox) (2 trials)

zolpidem (ambien) (3 trials)

Drugs in Phase 2 Trials (8)

Key: Paratek Pharmaceuticals Inc (2) Acquired (6)

banoxantrone (3 trials)

erlotinib (tarceva) (1 trial)

gemcitabine (gemzar) (1 trial)

levofloxacin (levaquin) (1 trial)

naproxen (naprosyn) (1 trial)

nitrofurantoin (furadantin) (1 trial)

ondansetron (zofran) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Paratek Pharmaceuticals Inc (0) Acquired (1)

zopiclone (1 trial)

Indications

Approved Indications


 

Pneumonia, Bacterial

Staphylococcal Skin Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 3)

Communicable Diseases (Phase 3)

Community-Acquired Infections (Phase 3)

Cystic Fibrosis (Phase 4)

Cystitis (Phase 2)

Fibrosis (Phase 4)

Infections (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pyelonephritis (Phase 2)

Skin Diseases (Phase 3)

Skin Diseases, Bacterial (Phase 3)

Skin Diseases, Infectious (Phase 3)

Soft Tissue Infections (Phase 3)

Urinary Tract Infections (Phase 2)

Wound Infection (Phase 1)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 15